JP Morgan Maintains Overweight on Medline, Lowers Price Target to $46
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Lisa Gill maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $53 to $46.
JP Morgan analyst Lisa Gill maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $53 to $46.